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Abstract 21 
Tumor heterogeneity is reflected and influenced by genetic, epigenetic and metabolic 22 
differences in cancer cells and their interactions with a complex microenvironment. This 23 
heterogeneity has resulted in the stratification of tumors into subtypes, mainly based on cancer-24 
specific genomic or transcriptomic profiles. Subtyping can lead to biomarker identification for 25 
personalized diagnosis and therapy, but stratification alone does not explain the origins of 26 
tumor heterogeneity. Heterogeneity has traditionally been thought to arise from distinct 27 
mutations/aberrations in “driver” oncogenes. However, certain subtypes appear to be the result 28 
of adaptation to the disrupted microenvironment caused by abnormal tumor vasculature 29 
triggering metabolic switches. Moreover, heterogeneity persists despite the predominance of 30 
single oncogenic driver mutations, perhaps due to second metabolic or genetic “hits”. In certain 31 
cancer types, existing subtypes have metabolic and transcriptomic phenotypes that are 32 
reminiscent of normal differentiated cells, whereas others reflect the phenotypes of stem or 33 
mesenchymal cells. The cell-of-origin may, therefore, play a role in tumor heterogeneity. In 34 
this mini-review, we focus on how cancer cell-specific heterogeneity is driven by different 35 
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genetic or metabolic factors alone or in combination using specific cancers to illustrate these 36 
concepts. 37 
 38 
 39 
 40 
Introduction 41 
Tumor heterogeneity refers to variations in genotype and phenotype between different tumors 42 
(inter-tumoral heterogeneity) or cells in a single tumor (intra-tumoral heterogeneity). The 43 
existence of inter-tumoral heterogeneity is well established and illustrated by the gene 44 
expression profiles used to stratify multiple cancer types, including, but not limited to, 45 
leukemias, glioblastoma, breast, pancreatic and colorectal tumors into their molecular subtypes 46 
(1-6). However, the true extent of intra-tumoral molecular heterogeneity is only just being 47 
elucidated, in part due to the recent exploitation of high-throughput genomic analyses of 48 
multiple biopsies from individual tumors or by the isolation and analysis of single cells (7). In 49 
general, heterogeneity in cancer cells can manifest itself in two key ways: first, by major 50 
genetic events such as somatic copy number aberrations (SCNAs) and mutations; and second, 51 
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phenotypic variations in transcript and protein expression levels, and, not insignificantly, major 52 
metabolic rewiring. These processes are mediated by, for instance, epigenetic programming.  53 
 54 
Microenvironment, Genetic and Metabolic Changes 55 
The Microenvironment and Nutrients Influence Metabolic Changes in Tumors Besides 56 
genetic differences, individual tumors also show differences in phenotypes including 57 
metabolism (5, 8). Malignant solid tumors frequently encounter mild to severe hypoxia 58 
(oxygen deficiency) due to insufficient tumor microvasculature quality and quantity, 59 
culminating in impaired oxidative phosphorylation (OXPHOS). This cellular stress induces 60 
changes in tumor transcription, respiration and metabolism, promoting highly abnormal 61 
neovasculature formation and, ultimately, allowing increased cancer cell survival, 62 
proliferation, invasion and metastasis (9). These cancer cells, independent of their oxygenation, 63 
increase glycolysis and produce more lactate (the Warburg effect) (10). Instead, the Pasteur 64 
effect states that presence of oxygen would inhibit glycolysis (11), suggesting that under 65 
normoxic conditions cancer cells may prefer OXPHOS. Irrespective of these different effects, 66 
highly metastatic prostate cancer cell lines under normoxic conditions were shown to undergo 67 
glycolysis, while less metastatic lines were OXPHOS dependent (12). Similar effects have been 68 
seen in glioma cell lines (13). Although the apparent differences in energy metabolism in 69 
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different tumors are attributable to their intrinsic genetic, epigenetic, and microenvironmental 70 
characteristics, they may also represent distinct subtypes (9). 71 
 72 
An example of hypoxia directly influencing metabolic programming via gene expression is the 73 
activity of pyruvate kinase isoforms M1 and M2 (PKM1/2), which are essential energy 74 
metabolism regulators critically involved in the final stages of glycolysis. Under hypoxic 75 
conditions, cancer cells expressing only PKM2 proliferate faster than those expressing only 76 
PKM1 (14). PKM2 exists as a less active dimer and a more active tetramer, the former being 77 
highly expressed in proliferating cancer cells and allowing upstream metabolites to accumulate 78 
to meet increased nucleotide, amino acid and serine biosynthesis needs (refer review (15)). 79 
This differential expression of PKM2 isoforms may represent distinct tumor subtypes. 80 
 81 
Mutated Metabolic Genes as Cancer Drivers A more self-evident entwining of metabolism 82 
and genetics is when mutations in genes encoding metabolic enzymes are a first cancer “hit”. 83 
Isocitrate dehydrogenase 1 (IDH1) is an enzyme that converts α-ketoglutarate (α-KG) to citrate 84 
in the tricarboxylic acid (TCA) cycle (16). However, mutated IDH1 can convert α-KG to 2-85 
hydroxyglutarate (2HG), inhibiting enzymes controlling epigenetic methylation and 86 
consequently altering global gene expression (16). IDH1 mutations are implicated in glioma 87 
(17) and acute myeloid leukaemia (AML) pathogenesis (18) and, interestingly, mutated IDH1 88 
enrichment partially defines the proneural glioblastoma subtype (6). Additionally, succinate 89 
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dehydrogenase (SDH) and fumarate hydratase, enzyme complexes involved in TCA cycle, also 90 
have links with cancer (original papers referred in (19)). Germline mutations resulting in the 91 
loss of one subunit of the SDH complex, SDHB, have been confirmed in a rare subset of renal 92 
cell carcinoma (20), and has shown association with therapeutic response to temozolomide in 93 
metastatic pheochromocytoma or paraganglioma (21) . 94 
 95 
Non-Metabolic Driver Mutations Affect Metabolism Clearly, cancer is not only caused by 96 
mutations in genes directly involved in metabolism, and first-hit mutations in non-metabolic 97 
genes also indirectly remodel tumor metabolism. Specific gene mutations often drive 98 
tumorigenesis in a large proportion of cases: TP53 is the most frequently mutated gene in many 99 
cancers (22), and KRAS is a proto-oncogene mutated in over 90% of pancreatic ductal 100 
adenocarcinomas (PDAs) (23). In this latter case, advanced PDAs in a Kras-driven genetically 101 
engineered mouse (GEM) model are dependent on continued mutant Kras signaling, which 102 
stimulates glucose uptake and reprograms downstream anabolic metabolism (24). In addition, 103 
tumors with mutant KRAS are addicted to a non-canonical glutamine-supported metabolic 104 
pathway that drives their growth and upregulates aerobic glycolysis (25).  105 
 106 
However, the requirement of mutant KRAS for tumor maintenance is heterogeneous, with well-107 
differentiated epithelial cell lines – specifically the classical PDA subtype (see below) – being 108 
more reliant on KRAS signaling (3, 26). If mutations in particular genes like KRAS are 109 
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dominant cancer drivers in most cases of certain cancer types, what causes heterogeneity and 110 
different phenotypes in these tumors as the disease progresses?  111 
 112 
Possible Origins of Tumor Heterogeneity Based on Driver Aberrations Cancer subtypes are 113 
mainly associated with distinct first-hit driver aberrations in normal cells (refer (27)), however, 114 
they can be genetic or metabolic aberrations (Figure 1A – left and right panels). Nevertheless, 115 
second-hit metabolic changes could lead to phenotypic heterogeneity in several ways in less 116 
heterogeneous tumors. For example, in cases in which a single mutated gene (e.g., KRAS in 117 
PDA) usually initiates tumorigenesis as a first hit, we hypothesize that tumor heterogeneity is 118 
instigated by a second hit to metabolic reprogramming induced by the microenvironment 119 
(Figure 1A – left panel). Inconsistent oxygenation and nutrient provision by imperfect 120 
microvasculature could lead to considerable microenvironment-based variability in different 121 
tumor regions (and between different tumors), prompting metabolic adaptation to local 122 
conditions that threaten cellular survival. For instance, metabolic reprogramming arising from 123 
obesity-related insulin resistance or excess reactive oxygen species (ROS) from mitochondrial 124 
metabolism could influence cancer cell proliferation and render them vulnerable to 125 
heterogeneity-causing mutations (refer (9)). Similarly, second-hit molecular or genetic changes 126 
could lead to distinct tumor subtypes in less heterogeneous tumors. Due to the wide-ranging 127 
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effects of metabolic and molecular reprogramming on phenotype, these adaptations could be 128 
the origin of different genetic and epigenetic subtypes.  129 
  130 
Epigenetics Facilitates Metabolism-Transcription Feedback While both molecular and 131 
metabolic heterogeneity undoubtedly exist, their origin is debatable. Although tumor diversity 132 
is well represented by molecular/genetic profiles, this does not imply that the heterogeneity is 133 
completely molecular/genetic in origin. Gene expression is dependent on many factors 134 
including epigenetic modifications that regulate chromatin structure and DNA accessibility to 135 
transcriptional machinery. Epigenetic enzymes may be modulated not only by their own 136 
expression and that of their regulators, but also by the availability of metabolites they require 137 
as substrates or cofactors (28). For example, tet methylcytosine dioxygenase 2 (TET2) and 138 
lysine demethylase 3A (KDM3A) are two epigenetic enzymes that employ the metabolite α-139 
KG as a cofactor. In the presence of mutant IDH1, which can convert α-KG to 2HG (16) (see 140 
above), 2HG competitively inhibits α-KG’s binding to TET2 and KDM3A, influencing 141 
epigenetic marks (refer (29)). In this way, genetics, epigenetics and metabolism interact in a 142 
system to form a complex feedback mechanism.  143 
 144 
Evidently, interactions between the tumor microenvironment, metabolism, and genetics are 145 
diverse and complex. The microenvironment regulates metabolic pathways via the epigenome 146 
and also influences them directly (refer (28)). Genomic aberrations (e.g. mutations) can affect 147 
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metabolic genes and non-metabolic genes with indirect actions on metabolism (17). The 148 
different outcomes of these interactions are a potential source of the heterogeneity that can lead 149 
to distinct cancer subtypes. 150 
 151 
Context-Specific Molecular and Metabolic Heterogeneity 152 
Transcriptomic PanNET Subtypes and Their Associated Metabolic Profiles Given the 153 
potential for metabolic heterogeneity to influence cancer cell phenotypes and, by extension, 154 
tumor subtypes, it is sensible to analyze transcriptomic and metabolic profiles together when 155 
attempting to stratify patients. By jointly analyzing mRNA and microRNA (miR) 156 
transcriptomes, we recently stratified human PanNETs into three molecular subtypes with 157 
distinct metabolic profiles (5). One subtype, the “insulinoma-like tumors” (IT; with increased 158 
insulin production), showed increased pyruvate carboxylase (PC) and cytoplasmic malic 159 
enzyme 1 (ME1) expression consistent with active pyruvate cycling, a process utilized by 160 
mature β cells to sustain glucose-stimulated insulin secretion. In contrast, the “metastatic-like 161 
primary” (MLP) subtype showed greater monocarboxylate transporter 1 (SLC16A1/MCT1) and 162 
hexokinase 1 (HK1) expression, which is suppressed in mature β cells (5). Transcriptomic 163 
PanNET subtypes appear to have distinct metabolic preferences.  164 
 165 
Transcriptomic PDA Subtypes PDAs have often been regarded as homogeneous due to the 166 
overwhelming prevalence of driver KRAS mutations. However, for the first time, we 167 
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demonstrated that PDAs, like other cancers, can be classified into three gene expression 168 
subtypes using a 62-gene signature (PDAssigner) (3). One subtype, “classical PDAs”, is 169 
characterized by high adhesion-associated, ribosomal and epithelial gene expression, and 170 
elevated GATA6 expression (3), which is essential for pancreatic development (30). 171 
 172 
The second PDAssigner subtype shows high expression of tumor cell-derived exocrine genes 173 
and was hence named “exocrine-like” (3) (corroborated by Moffitt et al. (31)). We took 174 
particular care to enrich cancer cells by microdissection for PDA subtyping to identify cancer-175 
specific subtypes, and further validated the presence of exocrine-like subtype by performing 176 
immunohistochemistry to detect the cancer cell-specific expression of exocrine-like subtype 177 
proteins on gene expression subtype matched PDA samples (3). The presence of exocrine-like 178 
subtype was validated by Noll et al. (32), by deriving matched exocrine-like PDA patient-179 
derived xenograft tumors and cell lines. In addition, they have shown this subtype to be 180 
resistant to tyrosine kinase inhibitors and paclitaxel via a novel mechanism, suggesting the 181 
requirement for different personalized approach for this cancer subtype (32).  182 
 183 
The third subtype, the “quasi-mesenchymal PDAs” (QM-PDA), exhibits high mesenchymal 184 
gene expression, representing a possible association with cancer-associated fibroblasts/stroma. 185 
Moreover, we clearly demonstrated increased glycolytic gene expression, including MCT1, 186 
hexokinase 2 (HK2) and glucose transporter 3 (SLC2A3/GLUT3) in QM-PDAs. Hence, QM-187 
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PDAs are a highly glycolytic PDA subtype with worse prognosis than the classical and 188 
exocrine-like subtypes (3). These subtypes were validated by independent studies involving 189 
patient PDA tumors (31-33) and cell lines (8), and by ourselves using GEM model-derived 190 
PDA cell lines (34). Although referred to as “basal-like” (based on a similarly-named breast 191 
cancer subtype) in Moffitt et al. (31), the QM-PDA subtype nomenclature was chosen to reflect 192 
the presence of both tumor and stromal genes in the signature (3, 31). Interestingly, the PDA 193 
subtypes in Bailey et al. (33) almost entirely conformed to our PDAssigner subtypes, except 194 
for an additional “immunogenic” subtype, where their a) “squamous” subtype represent our 195 
QM-PDA subtype, b) “pancreatic progenitor” represent our classical subtype and c) “aberrantly 196 
differentiated endocrine exocrine (ADEX)” represent our exocrine-like subtype (33). 197 
Conversely, there was lower concordance between the Moffitt and Bailey subtypes (33). 198 
 199 
Importantly, classical and QM-PDA cell lines with different transcriptomes and metabolomes 200 
exhibit differential responses to two common therapies: classical PDA cell lines were more 201 
sensitive to erlotinib and QM-PDA lines to gemcitabine (3), despite increased mutant KRAS 202 
dependence in the classical subtype (3, 26). Patients with classical subtype tumors, therefore, 203 
may derive benefit from KRAS signaling related therapies, although this has yet to be realized 204 
clinically. However, this data provides clues as to why current clinical responses to erlotinib 205 
and gemcitabine in combination are heterogeneous in unselected PDA patients. Moffitt et al. 206 
have shown that basal-like (QM-PDA) subtype patients were associated with better response 207 
Cancer Research  Mini Review 
 12 
to adjuvant therapy compared to those with classical subtype PDA (31), further suggesting 208 
personalized treatment options in this aggressive cancer type. 209 
 210 
Metabolomic PDA Subtypes Complementary to the transcriptomic subtypes described above, 211 
metabolic profiling has also revealed three PDA subtypes (8): “glycolytic” PDAs (QM-PDAs), 212 
with elevated glycolysis and serine pathways, increased MCT1 expression, and high glutamine 213 
incorporation into TCA cycle metabolites; “lipogenic” PDAs (classical PDAs), with lipid and 214 
electron transport chain metabolite enrichment and high lipogenesis gene expression, high 215 
oxygen consumption and mitochondrial content, and high glucose incorporation into TCA 216 
cycle metabolites; and “slow proliferating” PDAs low in amino acids and carbohydrates. These 217 
subtype-specific cell lines were also shown to have different responses to various metabolism-218 
based inhibitors (8). 219 
 220 
Putative Cell-of-Origin and Metabolic Phenotypes 221 
An alternative hypothesis to distinct driver aberrations leading to different subtypes is that 222 
cancer cells with different cells-of-origin (27) or those which have undergone epithelial-223 
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mesenchymal transition (EMT) and having distinct molecular and/or metabolic profiles 224 
develop into distinct subtypes based on the cell’s metabolic dependencies (Figures 1B and C).  225 
 226 
The Cell-of-Origin/Phenotype of PanNETs Combined transcriptomic and metabolic profiling 227 
can reveal patterns in phenotypes of cancer subtypes that are reminiscent of their normal 228 
counterpart cells, probably reflecting different cellular origin. In PanNET, IT tumors are 229 
clinically characterized as well differentiated, functional (secrete insulin) and low grade (have 230 
low Ki67-based proliferation index), which infrequently metastasize, and share gene 231 
expression and metabolism with mature islet β cells. Conversely, the proliferation rate in IT 232 
cells is comparatively higher than in β cells irrespective of the infrequent somatic mutations in 233 
tumors (5). Hence, ITs are likely to arise from more differentiated β cells. In this way, they are 234 
probably similar to the exocrine PDA subtype (3) and enterocyte and goblet-like/metabolic 235 
colorectal cancer (CRC) subtypes (see below) (4), which all retain characteristics of their 236 
normal differentiated cells (all these are represented generally in Figure 1B – left panel). 237 
 238 
In contrast, MLP subtype tumors are poorly differentiated and non-functional (i.e. no hormones 239 
can be detected in the blood) and are associated with liver metastases and high tumor grades. 240 
This subtype possesses a typical pancreatic stem/precursor cells or immature β cell 241 
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transcriptional signature and expresses genes associated with fibroblasts, stroma, stem cells, 242 
and hypoxia (see Figure 1B).  243 
 244 
The Cell-of-Origin/Phenotype of Colorectal Tumors We discovered five clinically pertinent 245 
colorectal cancer (CRC) subtypes by mRNA profiling of 1,290 tumors (“stem-like”, “transit 246 
amplifying” (TA), “enterocyte”, “goblet-like”, and “inflammatory” subtypes) (4). 247 
Comparisons with known colon-crypt cell type gene signatures revealed likely cell-of-248 
origin/phenotype candidates (see Figure 1B). For example, the goblet-like and enterocyte 249 
subtype signatures were associated with those of the normal goblet and enterocyte cells (colon 250 
crypt top), while the stem-like subtype was associated with the crypt base, implicating these 251 
sites as the putative cell-of-origins for these subtypes. The stem-like subtype (with low 252 
differentiation marker expression) showed high stem cell, myoepithelial/mesenchymal and 253 
stromal gene expression.  254 
 255 
Although these profiles were subsequently independently confirmed (35), other studies have 256 
concluded that CRCs can be divided into between three and six subtypes (36). Reconciliation 257 
of these subtypes has revealed that these classifications were in fact in broad agreement for 258 
four subtypes, with the remainder being further subdivisions of these “consensus molecular 259 
subtypes” (CMS) (36). One of these four CMS subtypes, which maps to our differentiated 260 
goblet-like subtype, was dubbed the “metabolic” (or CMS3) subtype (36) due to its enrichment 261 
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for several metabolic gene signatures, and was associated with high KRAS mutation frequency, 262 
whose influence on metabolism is discussed above (24, 25). 263 
 264 
Epithelial and Mesenchymal Signatures in Cancer Subtypes EMT is a phenotypic switch in 265 
which cancer cells convert to a more invasive and metastasis-capable (mesenchymal) state. 266 
Since EMT is reversible it cannot simply be attributed to a genetic event, but instead is likely 267 
to represent a comprehensive reprogramming of the genetic, epigenetic, and metabolic profiles 268 
of the cell. This reprogramming is triggered by extracellular signaling, which results in genetic 269 
and metabolic adaptation to the microenvironment (refer (37)).  270 
 271 
Tumor stratification into subtypes can also reveal an epithelial or mesenchymal classification 272 
(Figure 1C). In PDA, the classical subtype expresses high levels of epithelial genes including 273 
CDH17 and CEACAM6, while QM-PDAs are enriched for the mesenchymal gene TWIST1 (3, 274 
8). In CRC, the stem-like (CMS4) subtype represents a mesenchymal phenotype, whereas 275 
goblet-like (CMS3) and enterocyte (subset of CMS2) CRCs represent epithelial phenotypes 276 
(4). Similarly, in PanNETs, the IT subtype exhibits differentiated cell-based markers, whereas 277 
MLPs have mesenchymal signature along with increased glycolytic genes. Moreover, the 278 
mouse MLP subtype can be further subdivided into those that express low or high insulin 279 
gene/protein (“MLP Ins-lo” and “Ins-hi”): the Ins-lo subtype probably originates from 280 
pancreatic stem/islet precursor cells (Figure 1B), while the Ins-hi tumors are likely to be the 281 
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result of epithelial-mesenchymal transition from mature β cells or the progression of β cell-282 
derived IT tumors based on their gene expression profiles (see Figure 1C) (5). This suggests 283 
that the epithelial and mesenchymal phenotypes in PanNET subtypes are products of their 284 
cells-of-origin and a consequence of subsequent reprogramming between the epithelial and 285 
mesenchymal states (5). Nevertheless, it would be interesting to examine the interactions of 286 
genetic, epigenetic and metabolic factors that trigger EMT in these subtypes. 287 
 288 
Concluding Remarks 289 
Overall, there appears to be at least three broad divisions of the origins of tumor heterogeneity 290 
and subtypes based on metabolic, genetic and/or molecular changes. The first are subtypes with 291 
initial tumorigenic driver genetic or metabolic aberration(s) that give rise to different tumor 292 
subtypes (Figure 1A – left and right panels). Nonetheless, an initial aberration as a first hit 293 
in their normal counterparts is probably followed by the gain of additional secondary genetic 294 
or metabolic aberration(s) that further drive progression and affect patient prognosis (Figure 295 
1A – left panel). In the second main group of cancers, cell-of-origin determines the subtypes, 296 
with certain differentiated subtypes maintaining the transcriptomic and other important 297 
characteristics of their well-differentiated normal counterparts (38) (e.g. pyruvate cycling (5)) 298 
and being addicted to more normal cellular energy metabolism. Most of these subtypes have 299 
favorable prognosis (Figure 1B – left panel). Others, probably originating from 300 
stem/precursor cells, are likely to shift their energy metabolism toward glycolysis and other 301 
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malignant metabolisms, and have a poorer prognosis (Figure 1B – right panel). Finally, the 302 
malignant potential and metabolic reprograming are inversely correlated with differentiated 303 
cell-based marker expression, with epithelial and mesenchymal/stemness signatures resulting 304 
in different prognoses (Figure 1C). Whether this context-specific metabolic reprogramming 305 
in different subtypes is triggered from the outset of tumor proliferation or occurs as a result of 306 
cellular adaptation still needs to be determined. 307 
 308 
Nevertheless, it has recently become clear that tumor heterogeneity influences therapeutic 309 
efficacy in a variety of cancer types. Stratifying patients into groups that best respond to 310 
treatment based on the individual tumor’s driver molecular aberrations has had clinical success. 311 
For example, tamoxifen and trastuzumab are two drugs that have subtype-specific benefits in 312 
patients with estrogen-receptor and HER2-positive breast cancers, respectively (39, 40). Our 313 
recent work and that of others has indicated that these molecular indicators of drug/subtype 314 
specificity are also likely to exist in other cancers (3, 4, 6, 31, 35, 41, 42). However, whether 315 
metabolic changes, cell-of-origin and EMT could be exploited for personalized/precise cancer 316 
therapies requires increased attention. 317 
 318 
 319 
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Figures 433 
Figure 1. Various origins of tumor heterogeneity. (A) Driver aberrations determine the 434 
characteristics of the ensuing tumor and, consequently, two driver aberrations (genetic or 435 
metabolic; aberration-1, e.g. KRAS mutation, shown as a red star inside the cell in the left panel, 436 
and a different one - aberration-2, e.g. an EGFR mutation, shown as a yellow star inside the 437 
cell in the right panel) can result in distinct tumor subtypes (Subtypes A or B). Subsequently, 438 
a second metabolic or genetic hit can determine tumor subtypes (left panel). A homogeneous 439 
tumor derived from a cell with a particular tumor-initiating driver aberration-1 can acquire a 440 
further metabolic or genetic hit for subsequent tumor progression. The nature of the second hit 441 
determines the associated characteristics of the progressing tumor subtype, leading to 442 
heterogeneity (Subtypes C or D). (B) Heterogeneity can arise depending on the cell-of-origin. 443 
In certain cases, tumors that arise from well-differentiated cells (e.g.,  cells) can result in a 444 
subtype (Subtype E) that maintains both the metabolic and genetic profiles of the original cell-445 
of-origin, and mostly have favorable prognosis (shown with a Kaplan-Meier curve). On the 446 
other hand, those tumors arising from stem/precursor cells with fewer markers of 447 
differentiation (Subtype F) probably have fewer metabolic and genetic characteristics of their 448 
parental cells and have a poorer prognosis (shown with a Kaplan-Meier curve). (C) EMT can 449 
lead to distinct tumor subtypes. Tumors originating from epithelial or mesenchymal cells can 450 
result in distinct subtypes (Subtypes G and H, respectively) with different prognoses (shown 451 
with a Kaplan-Meier curve). EMT is shown with a reversible arrow. 452 
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